Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07056699 · ClinicalTrials.gov registry record · Phase 3
SGLT2i, Pioglitazone, and Ketone Production in T1D
A Phase 3 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Not yet
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT07056699 is a Phase 3 study that has not yet begun recruiting, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 24 participants.
The verdict
NCT07056699, a Phase 3 study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center at San Antonio.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future. In patients with Type 1 Diabetes (T1D), Dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i) is known to increase production of glucose in the liver, increase breakdown of fats (lipolysis), and increase production of ketones (ketogenesis). Ketones are chemicals produced by the liver when the body breaks down fat for energy instead of glucose. When the level of ketones in the body becomes too high, a condition called ketoacidosis develops. In this study, the study team will investigate whether adding pioglitazone (a medication commonly used to treat type 2 diabetes), can reduce the Dapagliflozin - induced liver glucose production, fat break down (lipolysis) and ketone body production (ketogenesis) in patients with Type 1 Diabetes (T1D).
Interventions
- OTHER Placebo
- DRUG Dapagliflozin 10mg Tab
- DRUG Pioglitazone 15 MG and 30mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07056699
The ClinicalTrials.gov registry entry for NCT07056699 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07056699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07056699 about?
NCT07056699 is a clinical study titled "SGLT2i, Pioglitazone, and Ketone Production in T1D". Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future. In patients with Type 1 Diabetes (T1D), Dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i)...
What is the current status of trial NCT07056699?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2026-07-01. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07056699?
The interventions under investigation include: Placebo (OTHER), Dapagliflozin 10mg Tab (DRUG), Pioglitazone 15 MG and 30mg (DRUG).
Who is sponsoring clinical trial NCT07056699?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.